Literature DB >> 17439591

Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy.

S Aiko1, Y Yoshizumi, T Ishizuka, T Sakano, I Kumano, Y Sugiura, T Maehara.   

Abstract

Tumor regression is used widely as a measure of tumor response following radiation therapy or chemoradiation therapy (CRT). In cases of esophageal cancer, a different pattern of tumor shrinkage is often observed between primary tumors and metastatic lymph nodes (MLNs). Regression of MLNs surrounded by normal tissue may be a more direct measure of the response to CRT than regression of a primary tumor as exfoliative mechanical clearance does not participate in shrinkage of MLNs. In this study we evaluated the significance of the reduction rate (RR) of MLNs as a prognostic factor in esophageal cancer patients treated with neoadjuvant CRT. Forty-two patients with marked MLNs were selected from 93 patients with esophageal carcinoma who had received neoadjuvant CRT. The RRs of the primary tumor and the MLNs were calculated from computed tomography scans. In 20 patients, surgical resection was carried out following CRT. Univariate analysis was used to determine which of the following variables were related to survival: size of the primary tumor and MLNs; RRs of both lesions; degree of lymph node (LN) metastasis; clinical stage; and surgical resection. Multivariate analysis was then performed to assess the prognostic relevance of each variable. The primary tumor was larger than the MLNs in 69% of patients before CRT and in 40% of patients after CRT. In 79% of the patients, the RR of the primary tumor was greater than the RR of the MLNs. The results of the univariate analyses showed that a high RR of the MLNs and surgical resection after CRT were associated with significantly improved survival. The multivariate analysis demonstrated that the RR of MLNs had the strongest influence on survival. The RR of LN metastasis should be evaluated as an important prognostic predictor in patients with marked LN metastasis of esophageal cancer treated with CRT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17439591     DOI: 10.1111/j.1442-2050.2006.00624.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  4 in total

1.  Lymph Node Harvest During Esophagectomy Is Not Influenced by Use of Neoadjuvant Therapy or Clinical Disease Stage.

Authors:  Renato A Luna; James P Dolan; Brian S Diggs; Nathan W Bronson; Brett C Sheppard; Paul H Schipper; Brandon H Tieu; Benjamin T Feeney; Ken M Gatter; Gina M Vaccaro; Charles R Thomas; John G Hunter
Journal:  J Gastrointest Surg       Date:  2015-04-25       Impact factor: 3.452

2.  Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy.

Authors:  Po-Jung Su; Min-Hsien Wu; Hung-Ming Wang; Chia-Lin Lee; Wen-Kuan Huang; Chiao-En Wu; Hsien-Kun Chang; Yin-Kai Chao; Chen-Kan Tseng; Tzu-Keng Chiu; Nina Ming-Jung Lin; Siou-Ru Ye; Jane Ying-Chieh Lee; Chia-Hsun Hsieh
Journal:  Sci Rep       Date:  2016-08-17       Impact factor: 4.379

3.  YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.

Authors:  Honghai Dai; Yang W Shao; Xiaoling Tong; Xue Wu; Jiaohui Pang; Alei Feng; Zhe Yang
Journal:  Cancer Med       Date:  2019-12-18       Impact factor: 4.452

4.  Response evaluation after neoadjuvant chemoradiation by positron emission tomography-computed tomography for esophageal squamous cell carcinoma.

Authors:  Joon Suk Park; Joon Young Choi; Seung Hwan Moon; Yong Chan Ahn; Jeeyun Lee; Dohun Kim; Kwhanmien Kim; Young Mog Shim
Journal:  Cancer Res Treat       Date:  2013-03-31       Impact factor: 4.679

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.